Finch Therapeutics Group, Inc. — Cyborg Score 2/10
Challenged
Microbiome therapeutics
Strategic Profile
Finch has a robust intellectual property estate including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. The company is currently focused on navigating restructuring while preserving its valuable IP portfolio and therapeutic assets.
Cyborg Score Rationale
Following the Chapter 11 filing in March 2026, the company faces significant operational and strategic challenges. While the IP portfolio and scientific foundation remain strong, the bankruptcy filing creates substantial uncertainty regarding pipeline advancement, clinical development, and long-term viability.
Top Insights
Chapter 11 bankruptcy filing (March 22, 2026) creates critical uncertainty about pipeline development and capital availability
Robust IP estate with 70+ issued patents provides defensive positioning and potential licensing value during restructuring
Clinical candidates (FIN-211, FIN-524, FIN-525) target large markets (autism, IBD) but development trajectories compromised by financial distress
Strategic partnerships with Takeda and academic institutions provide potential collaboration leverage during reorganization
Named Competitors
SynsporeticTM — Engineered live biotherapeutic products for microbiome disorders
Microbiome Programs — Large pharma with microbiome research initiatives
OpenBiome — Nonprofit fecal microbiota repository and research organization